CAS: 83461-56-7; Mifamurtide
该化合物其结构特征为替代铬,主要被承认为具有聚合过程的光化剂作用,特别是在紫外线可保证的涂料和墨水中. MTP-PE在紫外线显示的频谱中表现出强烈的吸收作用,使其在接触紫外线时能够有效地开始聚合.该化合物在室内温度下一般是黄色至安培液体,在有机溶剂中可溶解.其再活动归因于碳基组的存在,该组在辐照时促进产生自由基.安全考虑包括谨慎地处理,因为它可能造成皮肤和眼刺激.此外,在远离光的冷干燥地方适当储存对于保持其稳定性和有效性至关重要.
- 英文名称Mifamurtide
- 中文名称米伐木肽
- IUPAC名称(2R)-3-(((((4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-((1R,2R)-1,2,3-trihydroxypropyl)-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl)oxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate
- 其它别名N-Acetylmuramyl-Alanyl-Isoglutaminyl-Alanyl-Sn-Glycero-3-Phosphoethano Lamine; Muramyl Tripeptide Phosphatidylethanolamine; Mifamurtide; N-(N-Acetylmuramoyl)-L-Alanyl-D-Alpha-Glutaminyl-N-[(7R)-4-Hydroxy-4-Oxido-10-Oxo-7-[(1-Oxohexadecyl)Oxy]-3,5,9-Trioxa-4-Phosphapentacos-1-Yl]-L-Alaninamide; L-Mtp-Pe. Mtp-Pe; Mtp-Pe
- CAS编号83461-56-7
- MFCD编号:MFCD09954133
- FDA UNII编号:1LM890Q4FY
- 分子式:C59H109N6O19P分子量:1237.52
- 产品CID: 1823296
- 同类组份化合物CAS83461-56-7 (free acid)90825-43-7 (sodium)838853-48-8 (sodium hydrate)
- 产品分类生物化工 → 多肽
- 相似结构搜索
- 产品信息参考
- InChIKey: ZVLWUMPAHCEZAW-KRNLDFAISA-N
- ZVLWUMPAHCEZAW-HYGHKABSNA-N
- 计算化学: 氢键受体数19.0氢键供体数10.0可旋转键数58.0
物理性质
MSDS等安全信息
- 警示词warning
- 危险描述H303 May be harmful if swallowed+H313 Skin contact may be harmful+H333 Inhalation may be harmful to the body
- 防范说明P264Thoroughly clean after treatmentP280Wear protective gloves/Wear protective clothing/Wear protective goggles/Wear a protective maskP305If it enters the eyesP351Rinse carefully with water for a few minutesP338Remove the contact lens(If any)And easy to operate,Continue flushingP337If eye irritation persistsP313Obtain medical advice/care
- 安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- WGK Germany3
合成工艺路线路线简述
海关参考信息
- 2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
2905399001-1,3-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2020354404-A1
优先权日:2019-05-09
标 题 :Peptidomimetic agents, synthesis and uses thereof
发明人：AL-ABED YOUSEF
权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
摘要:Compounds for use in synthesis of peptidomimetic agents; synthesis of peptidomimetic agents; peptidomimetic diagnostic and therapeutic agents; and uses of the compounds and peptidomimetic agents in drug discovery, diagnosis, prevention and treatment of diseases are described.
专利号:US-10919882-B2
优先权日:2019-05-09
标题:Compounds for use in synthesis of peptidomimetics
专利号:US-11414405-B2
优先权日:2019-05-09
标 题:Compounds for use in synthesis of peptidomimetics
专利号:EP-3965770-A1
优先权日:2019-05-09
标 题 :Compounds for use in synthesis of peptidomimetics
专利号:US-2021130331-A1
优先权日:2019-05-09
标 题:Compounds for use in synthesis of peptidomimetics
专利号:CA-3174239-A1
优先权日:2020-05-08
标题:Dimers for use in synthesis of peptidomimetics
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Song HJ, Lee JA, Han E, Lee EK. Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis. Tumour Biol. 2015 Apr 3. [Epub ahead of print] doi: 10.1586/14737167.2015.972378. Epub 2014 Oct 29. doi: 10.1007/s13277-014-2139-y. Epub 2014 May 30. doi: 10.1016/j.jval.2013.08.2294. Epub 2013 Oct 3. doi: 10.1002/jlcr.3078. Epub 2013 Jul 9. doi: 10.1111/bcp.12261.
7: Venkatakrishnan K, Liu Y, Noe D, Mertz J, Bargfrede M, Marbury T, Farbakhsh K, Oliva C, Milton A. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment. Br J Clin Pharmacol. 2014 Jun;77(6):986-97. doi: 10.1111/bcp.12260.
8: Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, Huh W, Sutphin R, Vyas YM, Shen V, Warwick A, Yeager N, Oliva C, Wang B, Liu Y, Chou A. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer. 2014 Feb;61(2):238-44. doi: 10.1002/pbc.24686. Epub 2013 Aug 31. doi: 10.1007/s00228-012-1262-1. Epub 2012 Mar 30. doi: 10.1517/14656566.2011.543129. Review.
合成参考文献
参考文献:10.1089/aid.1990.6.1157
摘要:Lazdins JK, Woods-Cook K, Walker M, Alteri E. The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages. AIDS Res Hum Retroviruses. 1990 Oct;6(10):1157–61. doi: 10.1089/aid.1990.6.1157.
📝 需求与反馈
尽可能描述清楚需求与问题信息
